Kochli Channappa Niranjan1, Niharika Abhay Sarathy2. 1. Department of Oral and Maxillofacial Pathology, SDM College of Dental Sciences and Hospital, Dharwad 580 009, Karnataka, India. Electronic address: niranjankc@sdmcds.edu. 2. Department of Oral and Maxillofacial Pathology, SDM College of Dental Sciences and Hospital, Dharwad 580 009, Karnataka, India.
Abstract
BACKGROUND: Several prognostic indicators have been used for many decades in an attempt to predict clinical behaviour of Oral Squamous Cell Carcinoma (OSCC). The prognostic value of TSR is yet to be explored in OSCC. Hence, the aim of the present study was to evaluate the prognostic value of TSR in OSCC patients. METHODOLOGY: A cohort of 60 histologically diagnosed cases of OSCC who underwent Radical Neck Dissection was included in the study. TSR was assessed and patients with >50% intratumor stroma were quantified as the stroma-poor group and those with <50% as the stroma-rich group. RESULTS: The parametric tests were performed for the statistical evaluation of TSR with the clinico-pathological variables and the survival. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 95.23% and 69.04%, respectively, in stroma-poor group and 77% and 44%, respectively in the stroma-rich group. CONCLUSION: TSR may serve as a reliable histologic prognostic indicator in OSCC and could be used in routine diagnostic pathology.
BACKGROUND: Several prognostic indicators have been used for many decades in an attempt to predict clinical behaviour of Oral Squamous Cell Carcinoma (OSCC). The prognostic value of TSR is yet to be explored in OSCC. Hence, the aim of the present study was to evaluate the prognostic value of TSR in OSCC patients. METHODOLOGY: A cohort of 60 histologically diagnosed cases of OSCC who underwent Radical Neck Dissection was included in the study. TSR was assessed and patients with >50% intratumor stroma were quantified as the stroma-poor group and those with <50% as the stroma-rich group. RESULTS: The parametric tests were performed for the statistical evaluation of TSR with the clinico-pathological variables and the survival. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 95.23% and 69.04%, respectively, in stroma-poor group and 77% and 44%, respectively in the stroma-rich group. CONCLUSION: TSR may serve as a reliable histologic prognostic indicator in OSCC and could be used in routine diagnostic pathology.
Authors: Alhadi Almangush; Rasheed Omobolaji Alabi; Giuseppe Troiano; Ricardo D Coletta; Tuula Salo; Matti Pirinen; Antti A Mäkitie; Ilmo Leivo Journal: BMC Cancer Date: 2021-04-30 Impact factor: 4.430
Authors: Kiki M H Vangangelt; Andrew R Green; Isabelle M F Heemskerk; Danielle Cohen; Gabi W van Pelt; Marcelo Sobral-Leite; Marjanka K Schmidt; Hein Putter; Emad A Rakha; Rob A E M Tollenaar; Wilma E Mesker Journal: Int J Cancer Date: 2020-01-22 Impact factor: 7.396
Authors: Tuula Salo; Ilmo Leivo; Alhadi Almangush; Ibrahim O Bello; Ilkka Heikkinen; Jaana Hagström; Caj Haglund; Luiz Paulo Kowalski; Pentti Nieminen; Ricardo D Coletta; Antti A Mäkitie Journal: Virchows Arch Date: 2020-09-21 Impact factor: 4.064